ruxolitinib
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Myelofibrosis
Conditions
Primary Myelofibrosis, Post-Polycythemia Vera-Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
Trial Timeline
Mar 31, 2017 → Feb 15, 2019
NCT ID
NCT02966353About ruxolitinib
ruxolitinib is a phase 2 stage product being developed by Novartis for Primary Myelofibrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02966353. Target conditions include Primary Myelofibrosis, Post-Polycythemia Vera-Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis.
What happened to similar drugs?
20 of 20 similar drugs in Primary Myelofibrosis were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (16)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05269771 | Pre-clinical | Completed |
| NCT04745637 | Pre-clinical | Active |
| NCT04337359 | Pre-clinical | Completed |
| NCT06824103 | Approved | Recruiting |
| NCT06462469 | Approved | Recruiting |
| NCT03491215 | Phase 1/2 | Completed |
| NCT02966353 | Phase 2 | Completed |
| NCT02292446 | Phase 3 | Completed |
| NCT02091752 | Phase 2 | Terminated |
| NCT02049450 | Phase 2 | Completed |
| NCT02072057 | Phase 2 | Terminated |
| NCT02015208 | Phase 1/2 | Completed |
| NCT02087059 | Phase 3 | Completed |
| NCT01877005 | Phase 2 | Completed |
| NCT01317875 | Phase 1 | Completed |
| NCT01392443 | Phase 2 | Completed |
Competing Products
20 competing products in Primary Myelofibrosis